Auto-contouring may reduce workload, interobserver variation, and time associated with manual contouring of organs at risk. Manual contouring remains the standard due in part to uncertainty around the time and workload savings after accounting for the review and editing of auto-contours. This preliminary study compares a standard manual contouring workflow with 2 auto-contouring workflows (atlas and deep learning) for contouring the bladder and rectum in patients with prostate cancer. Methods and Materials: Three contouring workflows were defined based on the initial contour-generation method including manual (MAN), atlas-based auto-contour (ATLAS), and deep-learning auto-contour (DEEP). For each workflow, initial contour generation was retrospectively performed on 15 patients with prostate cancer. Then, radiation oncologists (ROs) edited each contour while blinded to the manner in which the initial contour was generated. Workflows were compared by time (both in initial contour generation and in RO editing), contour similarity, and dosimetric evaluation. Results: Mean durations for initial contour generation were 10.9 min, 1.4 min, and 1.2 min for MAN, DEEP, and ATLAS, respectively. Initial DEEP contours were more geometrically similar to initial MAN contours. Mean durations of the RO editing steps for MAN, DEEP, and ATLAS contours were 4.1 min, 4.7 min, and 10.2 min, respectively. The geometric extent of RO edits was consistently larger for ATLAS contours compared with MAN and DEEP. No differences in clinically relevant dose-volume metrics were observed between workflows. Conclusion: Auto-contouring software affords time savings for initial contour generation; however, it is important to also quantify workload changes at the RO editing step. Using deep-learning auto-contouring for bladder and rectum contour generation reduced contouring time without negatively affecting RO editing times, contour geometry, or clinically relevant doseevolume metrics.

Computed tomography dose index (CTDI) is a conventional indicator of the patient dose in CT studies. It is measured as the integration of the longitudinal single scan dose profile (SSDP) by using a 100-mm-long pencil ionization chamber and a single axial scan. However, the assumption that most of the SSDP is contained within the chamber length may not be valid even for thin slices. We have measured the SSDPs for several slice widths on two CT scanners using a PTW diamond detector placed in a 300 mm x 200 mm x 300 mm water-equivalent plastic phantom. One SSDP was also measured using lithium fluoride (LiF) TLDs and an IC-10 small volume ion chamber, verifying the general shape of the SSDP measured using the diamond detector. Standard cylindrical PMMA CT phantoms (140 mm length) were also used to qualitatively study the effects of phantom shape, length, and composition on the measured SSDP. The SSDPs measured with the diamond detector in the water-equivalent phantom were numerically integrated to calculate the relative accumulated dose D(L)(0)calc at the center of various scan lengths L. D(L)(0)calc reached an equilibrium value for L > 300 mm, suggesting the need for phantoms longer than standard CT dose phantoms. We have also measured the absolute accumulated dose using an IC-10 small volume ion chamber, D(L)(0)SV, at three points in the phantom cross section for several beamwidths and scan lengths. For one CT system, these measurements were made in both axial and helical scanning modes. The absolute CTDI100, measured with a 102 mm active length pencil chamber, were within 4% of D(L)(0)SV measured with the small volume ion chamber for L approximately 100 mm suggesting that nonpencil chambers can be successfully used for CT dosimetry. For nominal beam widths ranging from 3 to 20 mm and for L approximately 250 mm, D(L)(0)SV values at the center of the water-equivalent phantom's elliptic cross section were approximately 25%-30% higher than the measured CTDI100. For small beamwidths, the difference in D(L)(0)SV for L approximately 250 mm and L approximately 14 x beamwidth (CTDI14nT) reached up to 50%. Peripheral point doses at 70 mm depth along the major axis of the phantom for L approximately 250 mm were up to 22% higher than for L approximately 100 mm. The differences between CTDI100 and D(L)(0)SV for L approximately 250 mm were in good agreement with the predictions made from the numerical integration of the measured SSDPs. Due to the considerable dose measured beyond the length of standard CT phantoms, CT dosimetry for longer body scan series should be performed in longer phantoms. Measurements could be made as we have shown, using a small volume chamber translating through the beam using multiple scans.

The purpose of this work was to investigate the influence of a new transmission detector on 6 MV x-ray beam properties. The device, COMPASS (IBA Dosimetry, Germany), contains 1600 plane parallel ionization chambers with a detector spacing of 6.5 mm and an active volume of 0.02 cm3. Surface dose measurements were carried out using a Markus chamber and radiochromic film for a range of field sizes and source-to-surface distances (SSDs). The surface dose and dose in the build-up region for COMPASS fields were compared to open fields. For moderately narrow beam geometric conditions, the increase in surface dose was small. For the largest field size investigated (20x20 cm2) at a 90 cm SSD, the surface dose with the detector was 34.9% versus 26.8% in the open field. However, the increase in surface dose in COMPASS fields was less than that observed with a standard block tray in the field (38.7% in the above example). It was found that beyond dmax, the difference in relative dose (profiles and PDDs) between open and COMPASS fields was insignificant. The mean transmission factor of the detector was 0.967 (standard deviation=0.002) measured over a range of field sizes from 3x3 to 20x20 cm2 at SSDs from 70 cm to 90 cm. In summary, the transmission detector was found to increase the relative dose in the buildup region but had a negligible effect on the beam parameters beyond dmax.

No abstract

IMPORTANCEWomen with large breast size treated with adjuvant breast radiotherapy (RT) have a high rate of acute toxic effects of the skin. Breast RT in the prone position is one strategy that may decrease these toxic effects.OBJECTIVE To determine if breast RT in the prone position reduces acute toxic effects of the skin when compared with treatment in the supine position.DESIGN, SETTING, AND PARTICIPANTS This phase 3, multicenter, single-blind randomized clinical trial accrued patients from 5 centers across Canada from April 2013 to March 2018 to compare acute toxic effects of breast RT for women with large breast size (bra band Ն40 in and/or ՆD cup) in the prone vs supine positions. A total of 378 patients were referred for adjuvant RT and underwent randomization. Seven patients randomized to supine position were excluded (5 declined treatment and 2 withdrew consent), and 14 patients randomized to prone position were excluded (4 declined treatment, 3 had unacceptable cardiac dose, and 7 were unable to tolerate being prone). Data were analyzed from April 2019 through September 2020. INTERVENTIONS Patients were randomized to RT in the supine or prone position. From April 2013 until June 2016, all patients (n = 167) received 50 Gy in 25 fractions (extended fractionation) with or without boost (range, 10-16 Gy). After trial amendment in June 2016, the majority of patients (177 of 190 [93.2%]) received the hypofractionation regimen of 42.5 Gy in 16 fractions. MAIN OUTCOMES AND MEASURES Main outcome was moist desquamation (desquamation).RESULTS Of the 357 women (mean [SD] age, 61 [9.9] years) included in the analysis, 182 (51.0%) were treated in the supine position and 175 (49.0%) in prone. There was statistically significantly more desquamation in patients treated in the supine position compared with prone (72 of 182 [39.6%] patients vs 47 of 175 [26.9%] patients; OR, 1.78; 95% CI, 1.24-2.56; P = .002), which was confirmed on multivariable analysis (OR, 1.99; 95% CI, 1.48-2.66; P < .001), along with other independent factors: use of boost (OR, 2.71; 95% CI, 1.95-3.77; P < .001), extended fractionation (OR, 2.85; 95% CI, 1.41-5.79; P = .004), and bra size (OR, 2.56; 95% CI, 1.50-4.37; P < .001).CONCLUSIONS AND RELEVANCE This randomized clinical trial confirms that treatment in the prone position decreases desquamation in women with large breast size receiving adjuvant RT. It also shows increased toxic effects using an RT boost and conventional fractionation.